glucagon receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-10. Anything still debated is marked as such rather than presented as settled.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Edema collection of fluid in the tissues of a part of the body. Diabetics often have edemic feet due to the impaired circulation in them. Electromyography EMG Test used to diagnose neuropathy and check for nerve damage. It uses electrodes to measure speed of nerve signal transmission. Damaged nerves have characteristic changes in transmission. Endocrine glands several glands and tissues which secrete signaling chemicals (almost always in very very small quantities) which control the function of other tissues. Insulin is produced by the endocrine part of the pancreas (i.e., beta cells) and is the primary hormone controlling metabolism. Endocrinologist a physician with special training in the operation and diseases of the endocrine system (i.e., the endocrine glands and tissues). Endogenous Grown or made inside the body. Insulin made by a person's own pancreas is endogenous insulin. Insulin that is supplied from outside the body (i.e., injected or otherwise supplied) is exogenous. End-stage renal disease (ESRD) The final phase of many kidney diseases; treated by dialysis or kidney transplantation. See also: Dialysis; nephropathy. Enzymes proteins which have the effect of greatly increasing the reaction rate of specific chemical reactions. Reaction rates are controlled by activation energies specific to particular reactions, and enzymes have the effect of lowering the activation energy. In general enzymes are chemicals which are not consumed by the reaction. In that sense, they are catalysts. Epidemiology the study of the transmission of diseases.
Depleted uranium (DU), also referred to in the past as Q-metal, depletalloy, or D-38, is uranium with a lower content of the fissile isotope 235U than natural uranium. The less radioactive and non-fissile 238U is the main component of depleted uranium. It is antonymous to "enriched uranium". Uranium is notable for the extremely high density of its metallic form: at 19.1 grams per cubic centimetre (0.69 lb/cu in), uranium is 68.4% more dense than lead. Because depleted uranium has nearly the same density as natural uranium but far less radioactivity, it is desirable for applications that demand high mass without added radiation hazards. Civilian uses include counterweights in aircraft, radiation shielding in medical radiation therapy, research and industrial radiography equipment, and containers for transporting radioactive materials. Military uses include armor plating and armor-piercing projectiles. The use of DU in ammunitions is controversial because of concerns about potential long-term health effects. Normal functioning of the kidney, brain, liver, heart, and numerous other systems can be affected by exposure to uranium, a toxic metal. It is only weakly radioactive because of the long radioactive half-life of 238U (4.468 billion years) and the low amounts of 234U (half-life about 246,000 years) and 235U (half-life 700 million years). The biological half-life (the average time it takes for the human body to eliminate half the amount in the body) for uranium is about 15 days.
Several experts called the U.S. airdrops performative and said they would do little to alleviate the famine in Gaza. Biden continued to support Israel during the course of the war despite significant domestic opposition to American involvement in it and subsequent widespread protests. A March 2024 Gallup poll found that a strong majority of Americans disapproved of Israeli conduct during the war. Beginning in April 2024, widespread Gaza war protests emerged on university campuses, denouncing Biden. On May 31, 2024, Biden announced his support for an Israeli ceasefire proposal, saying that Hamas was "no longer capable" of another large-scale attack. The proposal, which was intended to establish a permanent ceasefire, bring about the release of all hostages, and lead to the reconstruction of the Gaza Strip, was supported by Hamas officials after mediation by Egypt and Qatar. The Netanyahu administration responded that Israel's goals regarding "the destruction of Hamas military and governing capabilities" had not changed and that conditions would need to be met before it would agree to a ceasefire. In the first year of the war, it was estimated that the Biden administration had sent Israel at least $17.9 billion in military aid, a record. In about the same period, it sent Palestinians $1.2 billion in humanitarian aid. Biden was reported by journalist Bob Woodward to have clashed throughout the war with Netanyahu over his war strategy and lack of a postwar plan for Gaza.
Antipsychotics are routinely used, often in conjunction with mood stabilizers such as lithium/valproate, as a first-line treatment for manic and mixed episodes associated with bipolar disorder. The reason for this combination is the therapeutic delay of the aforementioned mood stabilizers (for valproate therapeutic effects are usually seen around five days after treatment is commenced whereas lithium usually takes at least a week before the full therapeutic effects are seen) and the comparatively rapid antimanic effects of antipsychotic drugs. The antipsychotics have a documented efficacy when used alone in acute mania/mixed episodes. At least five atypical antipsychotics (lumateperone, cariprazine, lurasidone, olanzapine, and quetiapine) have also been found to possess efficacy in the treatment of bipolar depression as a monotherapy, whereas only olanzapine and quetiapine have been proven to be effective broad-spectrum (i.e., against all three types of relapse—manic, mixed and depressive) prophylactic (or maintenance) treatments in patients with bipolar disorder. A recent Cochrane review also found that olanzapine had a less favourable risk/benefit ratio than lithium as a maintenance treatment for bipolar disorder. The American Psychiatric Association and the UK National Institute for Health and Care Excellence recommend antipsychotics for managing acute psychotic episodes in schizophrenia or bipolar disorder, and as a longer-term maintenance treatment for reducing the likelihood of further episodes.
Sources: en.wikipedia.org
== Documentation == The documentation of activities by pharmaceutical manufacturers is a license-to-operate endeavor, supporting both the quality of the product produced and satisfaction of regulators who oversee manufacturing operations and determine whether a manufacturing process may continue or must be terminated and remediated.
=== General and cited references === National Burn Repository 2012 Report (PDF). Dataset Version 8.0. Chicago: American Burn Association. 2012. Archived from the original (PDF) on 3 March 2016. Retrieved 20 April 2013.
Antithrombin I (AT I) refers to the binding of thrombin to fibrin, after thrombin has activated fibrinogen, at a non-catalytic binding site of thrombin. Antithrombin II (AT II) refers to a cofactor in plasma, which together with heparin interferes with the interaction of thrombin and fibrinogen. Antithrombin III (AT III) refers to a substance in plasma that inactivates thrombin. Antithrombin IV (AT IV) refers to an antithrombin that becomes activated during and shortly after blood coagulation. Only AT III and possibly AT I are medically significant. AT III is generally referred to solely as "antithrombin" and it is antithrombin III that is discussed in this article. Antithrombin has a half-life in blood plasma of around 3 days. The normal antithrombin concentration in human blood plasma is high at approximately 0.12 mg/ml, which is equivalent to a molar concentration of 2.3 μM. Antithrombin has been isolated from the plasma of a large number of species additional to humans. As deduced from protein and cDNA sequencing, cow, sheep, rabbit and mouse antithrombins are all 433 amino acids in length, which is one amino acid longer than human antithrombin. The extra amino acid is thought to occur at amino acid position 6. Cow, sheep, rabbit, mouse, and human antithrombins share between 84 and 89% amino acid sequence identity. Six of the amino acids form three intramolecular disulfide bonds, Cys8-Cys128, Cys21-Cys95, and Cys248-Cys430. They all have four potential N-glycosylation sites.
=== Xander Lindt === Xander Lindt (Gustav Lindh) is a cocky young heir of the Lindt chocolate empire, and a member of Henry's entourage. He repeatedly demeans Yasmin after she rejects his sexual advances at a Swiss climate conference.
Cannabis tea (also known as weed tea, pot tea, a cannabis decoction) is a cannabis-infused drink prepared by steeping various parts of the cannabis plant in hot or cold water. Cannabis tea is commonly recognized as an alternative form of preparation and consumption of the cannabis plant, more popularly known as marijuana, pot, or weed. This plant has long been recognized as an herbal medicine employed by health professionals worldwide to ease symptoms of disease, as well as a psychoactive drug used recreationally and in spiritual traditions. Though less commonly practiced than popular methods like smoking or consuming edibles, drinking cannabis tea can produce comparable physical and mental therapeutic effects. Such effects are largely attributed to the THC and CBD content of the tea, levels of which are drastically dependent on individual preparation techniques involving volume, amount of cannabis, and boiling time. Also in common with these administration forms of cannabis is the heating component performed before usage. Due to the rather uncommon nature of this particular practice of cannabis consumption in modern times (in contrast to historical use) as well as the legality of cannabis throughout the world, the research available on the composition of cannabis tea is limited and based broadly around what is known of cannabis as it exists botanically.
Sources: en.wikipedia.org
== Pathway == This enzyme acts as the second step of a biochemical pathway initiated by the creation of N-acylphosphatidylethanolamine, by means of the transfer of an acyl group from the sn-1 position of glycerophospholipid onto the amino group of phosphatidylethanolamine. While NAPE-PLD contributes to the biosynthesis of several NAEs in the mammalian central nervous system, it is not clear if this enzyme is not responsible for the formation of the endocannabinoid anandamide, since NAPE-PLD knockout mice have been reported to have wild-type levels or very reduced levels of anandamide. The N-acylethanolamines released by this enzyme become potential substrates for fatty acid amide hydrolase (FAAH), which hydrolyzes the free fatty acids from ethanolamine. Defects in this enzyme can cause NAPE-PLD products such as anandamide to build up to levels 15-fold higher than normally observed.
Fatty acid metabolism consists of various metabolic processes involving or closely related to fatty acids, a family of molecules classified within the lipid macronutrient category. These processes can mainly be divided into (1) catabolic processes that generate energy and (2) anabolic processes where they serve as building blocks for other compounds. In catabolism, fatty acids are metabolized to produce energy, mainly in the form of adenosine triphosphate (ATP). When compared to other macronutrient classes (carbohydrates and protein), fatty acids yield the most ATP on an energy per gram basis, when they are completely oxidized to CO2 and water by beta oxidation and the citric acid cycle. Fatty acids (mainly in the form of triglycerides) are therefore the foremost storage form of fuel in most animals, and to a lesser extent in plants. In anabolism, intact fatty acids are important precursors to triglycerides, phospholipids, second messengers, hormones and ketone bodies. For example, phospholipids form the phospholipid bilayers out of which all the membranes of the cell are constructed from fatty acids. Phospholipids comprise the plasma membrane and other membranes that enclose all the organelles within the cells, such as the nucleus, the mitochondria, endoplasmic reticulum, and the Golgi apparatus. In another type of anabolism, fatty acids are modified to form other compounds such as second messengers and local hormones. The prostaglandins made from arachidonic acid stored in the cell membrane are probably the best-known of these local hormones.
Bernoulli's principle predicts that the decrease in pressure is associated with an increase in speed; in other words, as the air passes over the paper, it speeds up and moves faster than it was moving when it left the demonstrator's mouth. But this is not apparent from the demonstration.
Gamma-glutamyltransferase is an enzyme that is overexpressed in cancer, and releases the chelator dithiocarbamate from the prochelator developed by Franz's research group, which forms a toxic copper complex. She works on iron chelators that can be used to remove deleterious iron in brain regions impacted by Parkinson's disease without damaging the healthy metal ions. The chelators developed by Franz have no affinity for iron until a mask is released by hydrogen peroxide, releasing a reactive oxygen species that combines with iron to form hydroxyl radicals. Additionally Franz studies copper-binding peptides such as histatin. Histatin binds to copper in vitro, but it is not clear how they interact or how the anti-fungal activity is modified. The Franz group have studied the anti-fungal activity of Histatin-5 against Candida albicans.
=== EC 1.3.1 With NAD+ or NADP+ as acceptor === EC 1.3.1.1: dihydrouracil dehydrogenase (NAD+) EC 1.3.1.2: dihydropyrimidine dehydrogenase (NADP+) EC 1.3.1.3: Δ4-3-oxosteroid 5β-reductase EC 1.3.1.4: transferred to EC 1.3.1.22, 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.5: cucurbitacin Δ23-reductase EC 1.3.1.6: fumarate reductase (NADH) EC 1.3.1.7: meso-tartrate dehydrogenase EC 1.3.1.8: acyl-CoA dehydrogenase (NADP+) EC 1.3.1.9: enoyl-[acyl-carrier-protein] reductase (NADH) EC 1.3.1.10: enoyl-[acyl-carrier-protein] reductase (NADPH, Si-specific) EC 1.3.1.11: 2-coumarate reductase EC 1.3.1.12: prephenate dehydrogenase EC 1.3.1.13: prephenate dehydrogenase (NADP+) EC 1.3.1.14: dihydroorotate dehydrogenase (NAD+) EC 1.3.1.15: dihydroorotate dehydrogenase (NADP+) EC 1.3.1.16: β-nitroacrylate reductase EC 1.3.1.17: 3-methyleneoxindole reductase EC 1.3.1.18: kynurenate-7,8-dihydrodiol dehydrogenase EC 1.3.1.19: cis-1,2-dihydrobenzene-1,2-diol dehydrogenase EC 1.3.1.20: trans-1,2-dihydrobenzene-1,2-diol dehydrogenase EC 1.3.1.21: 7-dehydrocholesterol reductase EC 1.3.1.22: 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.23: Identical to EC 1.3.1.3, Δ4-3-oxosteroid 5β-reductase EC 1.3.1.24: biliverdin reductase EC 1.3.1.25: 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase EC 1.3.1.26: Now EC 1.17.1.8, 4-hydroxy-tetrahydrodipicolinate reductase EC 1.3.1.27: 2-hexadecenal reductase EC 1.3.1.28: 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase EC 1.3.1.29: cis-1,2-dihydro-1,2-dihydroxynaphthalene dehydrogenase EC 1.3.1.30: transferred to EC 1.3.1.22, 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.31: 2-enoate reductase EC 1.3.1.32: maleylacetate reductase EC 1.3.1.33: protochlorophyllide reductase EC 1.3.1.34: 2,4 Dienoyl-CoA reductase (NADPH) EC 1.3.1.35: Now EC 1.14.19.22, microsomal oleoyl-lipid 12-desaturase EC 1.3.1.36: geissoschizine dehydrogenase EC 1.3.1.37: cis-2-enoyl-CoA reductase (NADPH) EC 1.3.1.38: trans-2-enoyl-CoA reductase (NADPH) EC 1.3.1.39: trans-2-enoyl-CoA reductase (NADPH) EC 1.3.1.40: 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate reductase EC 1.3.1.41: xanthommatin reductase EC 1.3.1.42: 12-oxophytodienoate reductase EC 1.3.1.43: arogenate dehydrogenase EC 1.3.1.44: trans-2-enoyl-CoA reductase (NAD+) EC 1.3.1.45: 2′-hydroxyisoflavone reductase EC 1.3.1.46: biochanin-A reductase EC 1.3.1.47: α-santonin 1,2-reductase EC 1.3.1.48: 13,14-dehydro-15-oxoprostaglandin 13-reductase EC 1.3.1.49: cis-3,4-dihydrophenanthrene-3,4-diol dehydrogenase EC 1.3.1.50: n Now EC 1.1.1.252 tetrahydroxynaphthalene reductase EC 1.3.1.51: 2′-hydroxydaidzein reductase EC 1.3.1.52: Now EC 1.3.8.5, 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.1.53: (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate dehydrogenase EC 1.3.1.54: precorrin-6A reductase EC 1.3.1.55: identical to EC 1.3.1.25, 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase EC 1.3.1.56: cis-2,3-dihydrobiphenyl-2,3-diol dehydrogenase EC 1.3.1.57: phloroglucinol reductase EC 1.3.1.58: 2,3-dihydroxy-2,3-dihydro-p-cumate dehydrogenase EC 1.3.1.59: There is no evidence that the enzyme exists EC 1.3.1.60: dibenzothiophene dihydrodiol dehydrogenase EC 1.3.1.61: identical to EC 1.3.1.53, (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate dehydrogenase EC 1.3.1.62: pimeloyl-CoA dehydrogenase EC 1.3.1.63: Now EC 1.21.1.2, 2,4-dichlorobenzoyl-CoA reductase EC 1.3.1.64: phthalate 4,5-cis-dihydrodiol dehydrogenase EC 1.3.1.65: 5,6-dihydroxy-3-methyl-2-oxo-1,2,5,6-tetrahydroquinoline dehydrogenase EC 1.3.1.66: cis-dihydroethylcatechol dehydrogenase EC 1.3.1.67: cis-1,2-dihydroxy-4-methylcyclohexa-3,5-diene-1-carboxylate dehydrogenase EC 1.3.1.68: 1,2-dihydroxy-6-methylcyclohexa-3,5-dienecarboxylate dehydrogenase EC 1.3.1.69: zeatin reductase EC 1.3.1.70: Δ14-sterol reductase EC 1.3.1.71: Δ24(241)-sterol reductase EC 1.3.1.72: Δ24-sterol reductase EC 1.3.1.73: 1,2-dihydrovomilenine reductase EC 1.3.1.74: 2-alkenal reductase [NAD(P)+] EC 1.3.1.75: 3,8-divinyl protochlorophyllide a 8-vinyl-reductase (NADPH) EC 1.3.1.76: precorrin-2 dehydrogenase EC 1.3.1.77: anthocyanidin reductase [(2R,3R)-flavan-3-ol-forming] EC 1.3.1.78: arogenate dehydrogenase (NADP+) EC 1.3.1.79: arogenate dehydrogenase (NAD(P)+) EC 1.3.1.80: Now classified as EC 1.3.7.12, red chlorophyll catabolite reductase EC 1.3.1.81: (+)-pulegone reductase EC 1.3.1.82: (-)-isopiperitenone reductase EC 1.3.1.83: geranylgeranyl diphosphate reductase EC 1.3.1.84: acrylyl-CoA reductase (NADPH) EC 1.3.1.85: crotonyl-CoA carboxylase/reductase EC 1.3.1.86: crotonyl-CoA reductase EC 1.3.1.87: 3-(cis-5,6-dihydroxycyclohexa-1,3-dien-1-yl)propanoate dehydrogenase EC 1.3.1.88: tRNA-dihydrouridine16/17 synthase (NAD(P)+) EC 1.3.1.89: tRNA-dihydrouridine47 synthase (NAD(P)+) EC 1.3.1.90: tRNA-dihydrouridine20a/20b synthase (NAD(P)+) EC 1.3.1.91: tRNA-dihydrouridine20 synthase (NAD(P)+) EC 1.3.1.92: artemisinic aldehyde Δ11(13)-reductase EC 1.3.1.93: very-long-chain enoyl-CoA reductase EC 1.3.1.94: polyprenol reductase EC 1.3.1.95: acrylyl-CoA reductase (NADH) EC 1.3.1.96: Botryococcus squalene synthase EC 1.3.1.97: botryococcene synthase EC 1.3.1.98: Now known to be catalyzed by two different enzymes, EC 1.3.1.122, (S)-8-oxocitronellyl enol synthase, and EC 5.5.1.34, (+)-cis,trans-nepetalactol synthase EC 1.3.1.100: chanoclavine-I aldehyde reductase EC 1.3.1.101: 2,3-bis-O-geranylgeranyl-sn-glycerol 1-phosphate reductase [NAD(P)H] EC 1.3.1.102: 2-alkenal reductase (NADP+) EC 1.3.1.103: 2-haloacrylate reductase EC 1.3.1.104: enoyl-[acyl-carrier-protein] reductase (NADPH) EC 1.3.1.105: 2-methylene-furan-3-one reductase EC 1.3.1.106: cobalt-precorrin-6A reductase EC 1.3.1.107: sanguinarine reductase EC 1.3.1.108: caffeoyl-CoA reductase EC 1.3.1.109: butanoyl-CoA dehydrogenase complex (NAD+, ferredoxin) EC 1.3.1.110: lactate dehydrogenase (NAD+,ferredoxin) EC 1.3.1.111: geranylgeranyl-bacteriochlorophyllide a reductase EC 1.3.1.112: anthocyanidin reductase [(2S)-flavan-3-ol-forming] EC 1.3.1.113: (4-alkanoyl-5-oxo-2,5-dihydrofuran-3-yl)methyl phosphate reductase EC 1.3.1.114: 3-dehydro-bile acid Δ4,6-reductase EC 1.3.1.115: 3-oxocholoyl-CoA 4-desaturase EC 1.3.1.116: 7β-hydroxy-3-oxochol-24-oyl-CoA 4-desaturase EC 1.3.1.117: hydroxycinnamoyl-CoA reductase EC 1.3.1.118: meromycolic acid enoyl-[acyl-carrier-protein] reductase EC 1.3.1.119: chlorobenzene dihydrodiol dehydrogenase EC 1.3.1.120: cyclohexane-1-carbonyl-CoA reductase NADP+) EC 1.3.1.121: 4-amino-4-deoxyprephenate dehydrogenase EC 1.3.1.122: (S)-8-oxocitronellyl enol synthase EC 1.3.1.123: 8-oxogeranial reductase EC 1.3.1.124: 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing]
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.